| Company/Division name | Bora Biologics |
| Parent company | Bora Pharmaceutical Group |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2026 |
| Offshore, work was done: | In-house |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 122.5 |
| Country(ies) from which reshored: | Taiwan, Province of China |
| City reshored to: | Rockville |
| State(s) reshored to: | MD |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | biologics |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Government Incentives, Proximity to customers/market, Under-utilized capacity |
